Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Im...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:British journal of cancer Ročník 124; číslo 2; s. 359 - 367
Hlavní autoři: Raskov, Hans, Orhan, Adile, Christensen, Jan Pravsgaard, Gögenur, Ismail
Médium: Journal Article
Jazyk:angličtina
Vydáno: London Nature Publishing Group UK 19.01.2021
Nature Publishing Group
Témata:
631/80/86/2371
692/4028/67/1059/2325
692/4028/67/327
Adverse events
Animals
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer immunotherapy
Cancer Research
CD8 antigen
Cell surface
Clinical trials
Cytotoxicity
Drug Resistance
Epidemiology
Humans
Immune checkpoint inhibitors
Immunotherapy
Immunotherapy - methods
Lymphocytes
Lymphocytes T
Molecular Medicine
Neoplasms - immunology
Oncology
Receptor mechanisms
Review
Review Article
T-Lymphocytes, Cytotoxic - immunology
ISSN:0007-0920, 1532-1827, 1532-1827
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8 + T cells with genetically modified receptors—chimaeric antigen receptors—to specify and enhance CD8 + T-cell functionality. New generations of cytotoxic T cells with genetically modified or synthetic receptors are being developed and evaluated in clinical trials. Furthermore, combinatory regimens might optimise treatment effects and reduce adverse events. This review summarises advances in research on the most prominent immune effectors in cancer and cancer immunotherapy, cytotoxic T cells, and discusses possible implications for future cancer treatment.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0007-0920
1532-1827
1532-1827
DOI:10.1038/s41416-020-01048-4